Features
Published | Updated

AstraZeneca: FDA Grants Priority Review to Blood Cancer Drug

By Rory Gallivan Dow Jones Newswires

LONDON – AstraZeneca PLC (AZN.LN) said Wednesday the U.S. Food and Drug Administration has granted priority review of the drug company's application for approval of its blood cancer treatment acalabrutinib.

AstraZeneca made a new drug application for the treatment after a Phase II trial.

The FDA grants priority review, which accelerates the assessment of drugs, to applications for medicines that, if approved, would offer a significant improvement in the treatment, diagnosis, or prevention of serious conditions.

Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

August 02, 2017 02:42 ET (06:42 GMT)